De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome

De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome
复制标题

具有 p210 BCR/ABL 和 t(1;16) 易位但不具有 t(9;22) Ph 染色体的新发急性巨核细胞白血病

DOI:
10.1186/1756-8722-4-45
复制
发表时间:
2011-11
期刊:
Journal of Hematology& Oncology
影响因子:
--
通讯作者:
zhang na
zhang na
中科院分区:
其他
文献类型:
--
作者:
liu yanan;li chunrui;xiaomin;zhang na

文献摘要

参考文献

相似文献

急性成巨核细胞白血病(AMKL)是急性髓细胞白血病(AML)的一种,其中大多数原始细胞为成巨核细胞。成年期新发AMKL很少见,预后极差。我们在此报告一位45岁女性,患有BCR/ABL重排及der(16)t(1;16)(q21;q23)易位但t(9;22)Ph染色体阴性的原发性AMKL。经诱导化疗组成的高三尖杉酯碱,阿糖胞苷和柔红霉素,病人达到部分血液学缓解。患者随后改用伊马替尼加一个周期的CAG方案(小剂量阿糖胞苷和阿糖胞苷联合粒细胞集落刺激因子),并达到完全缓解(CR)。40天后疾病复发,患者最终死于感染。据我们所知,这是首次报道的原发性AMKL伴p210 BCR/ABL和der(16)t(1;16)(q21;q23)易位,而非t(9;22)Ph染色体易位。
Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We here report a 45-year-old woman with de novo AMKL with BCR/ABL rearrangement and der(16)t(1;16)(q21;q23) translocation but negative for t(9;22) Ph chromosome. Upon induction chemotherapy consisting of homoharringtonine, cytarabine and daunorubicin, the patient achieved partial hematological remission. The patient was then switched to imatinib plus one cycle of CAG regimen (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor), and achieved complete remission (CR). The disease recurred after 40 days and the patient eventually died of infection. To the best of our knowledge, this is the first report of de novo AMKL with p210 BCR/ABL and der(16)t(1;16)(q21;q23) translocation but not t(9;22) Ph chromosome.
DOI: --
发表时间: 2000-10
期刊: The Journal of pharmacology and experimental therapeutics
影响因子: --
作者:
E. Buchdunger;C. Cioffi;N. M. Law;D. Stover;Sayuri Ohno-Jones;B. Druker;N. Lydon
通讯作者: E. Buchdunger;C. Cioffi;N. M. Law;D. Stover;Sayuri Ohno-Jones;B. Druker;N. Lydon
DOI: 10.1002/1097-0142(19900215)65:4
发表时间: 1990-02
期刊: Cancer
影响因子: 6.2
作者:
W. Chuang;Hong-Wen Liu;W. Chang
通讯作者: W. Chuang;Hong-Wen Liu;W. Chang
DOI: 10.1182/blood.v96.7.2405.h8002405_2405_2411
发表时间: 2000-10
期刊: Blood
影响因子: 20.3
作者:
Martin S. Tallman;D. Neuberg;John M. Bennett;Christopher J. François;E. Paietta;P. H. Wiernik;Gordon W. Dewald;P. Cassileth;Martin M. Oken;Jacob M. Rowe
通讯作者: Martin S. Tallman;D. Neuberg;John M. Bennett;Christopher J. François;E. Paietta;P. H. Wiernik;Gordon W. Dewald;P. Cassileth;Martin M. Oken;Jacob M. Rowe
DOI: 10.1182/blood-2001-12-0241
发表时间: 2002-07-15
期刊: BLOOD
影响因子: 20.3
作者:
Dastugue, N;Lafage-Pochitaloff, M;Berger, R
通讯作者: Berger, R
DOI: 10.1016/j.cancergencyto.2009.04.018
发表时间: 2009-09-01
影响因子: --
作者:
Ahmad, Firoz;Dalvi, Rupa;Mandava, Swarna
通讯作者: Mandava, Swarna